|
FY2026
12 months to Jun 30, 2026
|
FY2025
12 months to Jun 30, 2025
|
FY2024
12 months to Jun 30, 2024
|
FY2023
12 months to Jun 30, 2023
|
FY2022
12 months to Jun 30, 2022
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Cost of revenues | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Research and development expenses | |||||
| Less: participation by the NIAID, the IIA, Horizon Europe and other parties | |||||
| Less: participation by the NIAID, the IIA (each, as defined below) and Horizon Europe | |||||
| Research and development expenses, net | |||||
| General and administrative expenses | |||||
| Operating loss | |||||
| Other financial income (expenses), net | |||||
| Interest expense | |||||
| Total financial income (expenses), net | |||||
| Loss before taxes | |||||
| Tax benefit | |||||
| Net loss | |||||
| Net loss attributed to non-controlling interests | |||||
| Net loss attributed to shareholders | |||||
| Loss per share: | |||||
| Basic loss per share (in Dollars per share) | |||||
| Diluted loss per share (in Dollars per share) | |||||
| Weighted average number of shares used in computing basic loss per share (in Shares) | |||||
| Weighted average number of shares used in computing diluted loss per share (in Shares) | |||||
Loading...